WATERTOWN, MA, Triveni Bio, a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B.
Triveni Bio Inc., a biotech company advancing novel antibody treatments for I&I disorders, announced a $115 million Series B to support pipeline expansion. The round was led by Goldman Sachs Alternatives with significant participation from additional new investors Fidelity Management & Research Company and Deep Track Capital, and Series A investors Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, and Invus.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
By VC News Daily
Source: VC News Daily